These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7910716)

  • 21. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.
    Taylor CW; Chase EM; Whitehead RP; Rinehart JJ; Neidhart JA; Gonzalez R; Bunn PA; Hersh EM
    J Immunother (1991); 1992 Apr; 11(3):176-83. PubMed ID: 1515422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polychemotherapy in advanced malignant melanoma.
    Foppoli M; Citterio G; Polastri D; Guerrieri R
    Tumori; 1995; 81(2):102-6. PubMed ID: 7778212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
    Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
    Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
    Atzpodien J; Poliwoda H; Kirchner H
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
    Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
    Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
    Rosenberg SA; Lotze MT; Yang JC; Linehan WM; Seipp C; Calabro S; Karp SE; Sherry RM; Steinberg S; White DE
    J Clin Oncol; 1989 Dec; 7(12):1863-74. PubMed ID: 2685181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
    Facendola G; Locatelli MC; Pizzocaro G; Piva L; Pegoraro C; Pallavicini EB; Signaroldi A; Meregalli M; Lombardi F; Beretta GD
    Br J Cancer; 1995 Dec; 72(6):1531-5. PubMed ID: 8519672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.
    Lopez Hanninen E; Poliwoda H; Atzpodien J
    Cancer Biother; 1995; 10(1):21-4. PubMed ID: 7780483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.
    Merchant RE; McVicar DW; Merchant LH; Young HF
    J Neurooncol; 1992 Jan; 12(1):75-83. PubMed ID: 1541981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
    Lee KH; Talpaz M; Rothberg JM; Murray JL; Papadopoulos N; Plager C; Benjamin R; Levitt D; Gutterman J
    J Clin Oncol; 1989 Nov; 7(11):1726-32. PubMed ID: 2809685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients.
    Nicolini A; Mancini PA; Ferrari P; Anselmi L; Sagripanti A; Carpi A
    Biomed Pharmacother; 1996; 50(8):344-9. PubMed ID: 8952853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon.
    Atzpodien J; Kirchner H; Hänninen EL; Menzel T; Deckert M; Franzke A; Schomburg A; Poliwoda H
    Oncology; 1994; 51(3):273-5. PubMed ID: 8196911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
    Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
    Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
    Silagi S; Dutkowski R; Schaefer A
    Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
    Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.